CARISOPRODOL IMMEDIATE RELEASE- carisoprodol tablet
Vensun Pharmaceuticals, Inc.
HIGHLIGHTS OF PRESCRIBING INFORMATION
These highlights do not include all the information needed to use carisoprodol tablets USP safely and effectively. See full prescribing information for carisoprodol tablets USP.
CARISOPRODOL tablets USP for oral Use, C-IV
Initial U.S. Approval: 1959
INDICATIONS AND USAGE
DOSAGE AND ADMINISTRATION
• Recommended dose is 250 mg to 350 mg three times a day and at bedtime. (2) (2)
DOSAGE FORMS AND STRENGTHS
Tablets: 250 mg, 350 mg (3) (3)
WARNINGS AND PRECAUTIONS
• Due to sedative properties, may impair ability to perform hazardous tasks such as driving or operating machinery (5.1) (5)
• Additive sedative effects when used with other CNS depressants including alcohol (5.1) (5)
• Cases of abuse, Dependence, and withdrawal (5.2, 9.2, 9.3) (5)
• Seizures (5.3) (5)
• CNS depressants (e.g., alcohol, benzodiazepines, opioids, tricyclic antidepressants) - additive sedative effects (5.1 and 7.1) (7)
See 17 for PATIENT COUNSELING INFORMATION.
FULL PRESCRIBING INFORMATION: CONTENTS*
Limitation of Use
Carisoprodol tablets USP should only be used for short periods (up to two or three weeks) because adequate evidence of effectiveness for more prolonged use has not been established and because acute, painful musculoskeletal conditions are generally of short duration [see Dosage and Administration (2)].
350 mg Tablets: circular shaped, biconvex, white to off white colored, uncoated tablets, debossed "S" and "435" on one side and plain on the other side
Carisoprodol tablets USP has sedative properties (in the low back pain trials, 13% to 17% of patients who received carisoprodol tablets USP experienced sedation compared to 6% of patients who received placebo) [see ADVERSE REACTIONS (6.1)] and may impair the mental and/or physical abilities required for the performance of potentially hazardous tasks such as driving a motor vehicle or operating machinery. There have been post-marketing reports of motor vehicle accidents associated with the use of carisoprodol tablets USP.
Since the sedative effects of carisoprodol tablets USP and other CNS depressants (e.g., alcohol, benzodiazepines, opioids, tricyclic antidepressants) may be additive, appropriate caution should be exercised with patients who take more than one of these CNS depressants simultaneously.
Carisoprodol, the active ingredient in carisoprodol tablets USP, has been subject to abuse, dependence, and withdrawal, misuse, and criminal diversion. [see Drug Abuse and Dependence (9.1, 9.2, 9.3)]. Abuse of carisoprodol tablets USP poses a risk of overdosage which may lead to death, CNS and respiratory depression, hypotension, seizures, and other disorders [see Overdosage (10)].
Post-marketing experience cases of carisoprodol abuse and dependence have been reported in patients with prolonged use and a history of drug abuse. Although most of these patients took other drugs of abuse, some patients solely abused carisoprodol. Withdrawal symptoms have been reported following abrupt cessation of carisoprodol tablets USP after prolonged use. Reported withdrawal symptoms included insomnia, vomiting, abdominal cramps, headache, tremors, muscle twitching, ataxia, hallucinations, and psychosis. One of carisoprodol's metabolites, meprobamate (a controlled substance), may also cause dependence [see Clinical Pharmacology (12.3)].
To reduce the risk of carisoprodol tablets USP abuse assess the risk of abuse prior to prescribing. After prescribing, limit the length of treatment to three weeks for the relief of acute musculoskeletal discomfort, keep careful prescription records, monitor for signs of abuse and overdose, and educate patients and their families about abuse and on proper storage and disposal.
Because clinical studies are conducted under widely varying conditions, adverse reaction rates observed in clinical studies of a drug cannot be directly compared to rates in the clinical studies of another drug and may not reflect rates observed in practice.
The data described below are based on 1387 patients pooled from two double blind, randomized, multicenter, placebo controlled, one-week trials in adult patients with acute, mechanical, lower back pain [see Clinical Studies (14)]. In these studies, patients were treated with 250 mg of carisoprodol tablets USP, 350 mg of carisoprodol tablets USP, or placebo three times a day and at bedtime for seven days. The mean age was about 41 years old with 54% females and 46% males and 74 % Caucasian, 16 % Black, 9% Asian, and 2% other.
There were no deaths and there were no serious adverse reactions in these two trials. In these two studies, 2.7%, 2%, and 5.4%, of patients treated with placebo, 250 mg of carisoprodol tablets USP, and 350 mg of carisoprodol tablets USP, respectively, discontinued due to adverse events; and 0.5%, 0.5%, and 1.8% of patients treated with placebo, 250 mg of carisoprodol tablets USP, and 350 mg of carisoprodol tablets USP, respectively, discontinued due to central nervous system adverse reactions.
Table 1 displays adverse reactions reported with frequencies greater than 2% and more frequently than placebo in patients treated with carisoprodol tablets USP in the two trials described above.
| Table 1. Patients with Adverse Reactions in Controlled Studies
| Carisoprodol Tablets USP 250 mg
| Carisoprodol Tablets USP 350 mg
| Drowsiness|| 31 (6)|| 73 (13)|| 47 (17)
| Dizziness|| 11 (2)|| 43 (8)|| 19 (7)
| Headache|| 11 (2)|| 26 (5)|| 9 (3)
The following events have been reported during postapproval use of carisoprodol tablets USP. Because these reactions are reported voluntarily from a population of uncertain size, it is not always possible to reliably estimate their frequency or establish a causal relationship to drug exposure
Cardiovascular: Tachycardia, postural hypotension, and facial flushing [see Overdosage (10)].
Central Nervous System: Drowsiness, dizziness, vertigo, ataxia, tremor, agitation, irritability, headache, depressive reactions, syncope, insomnia, and seizures [see Overdosage (10)].
Gastrointestinal: Nausea, vomiting, and epigastric discomfort.
Hematologic: Leukopenia, pancytopenia
The sedative effects of carisoprodol tablets USP and other CNS depressants (e.g., alcohol, benzodiazepines, opioids, tricyclic antidepressants) may be additive. Therefore, caution should be exercised with patients who take more than one of these CNS depressants simultaneously. Concomitant use of carisoprodol tablets USP and meprobamate, a metabolite of carisoprodol tablets USP, is not recommended [see Warnings and Precautions (5.1)].
Carisoprodol USP is metabolized in the liver by CYP2C19 to form meprobamate [see Clinical Pharmacology (12.3)]. Co-administration of CYP2C19 inhibitors, such as omeprazole or fluvoxamine, with carisoprodol tablets USP could result in increased exposure of carisoprodol USP and decreased exposure of meprobamate. Co-administration of CYP2C19 inducers, such as rifampin or St. John's Wort, with carisoprodol tablets USP could result in decreased exposure of carisoprodol USP and increased exposure of meprobamate. Low dose aspirin also showed an induction effect on CYP2C19. The full pharmacological impact of these potential alterations of exposures in terms of either efficacy or safety of carisoprodol tablets USP is unknown.
Data over many decades of carisoprodol use in pregnancy have not identified a drug-associated risk of major birth defects, miscarriage, or other adverse maternal or fetal outcomes. Data on meprobamate, the primary metabolite of carisoprodol, also do not show a consistent association between maternal use of meprobamate and an increased risk of major birth defects (see Data).
In a published animal reproduction study, pregnant mice administered carisoprodol orally at 2.6-and 4.1-times the maximum recommended human dose ([MRHD] of 1400 mg per day [350 mg QID] based on body surface area [BSA] comparison) from gestation through weaning resulted in reduced fetal weights, postnatal weight gain, and postnatal survival (see Data).
The estimated background risk of major birth defects and miscarriage for the indicated population is unknown. All pregnancies have a background risk of birth defect, loss, or other adverse outcomes. In the U.S. general population, the estimated background risk of major birth defects and miscarriage in clinically recognized pregnancies is 2 to 4% and 15 to 20%, respectively.
Retrospective case-control and cohort studies of meprobamate use during the first trimester of pregnancy have not consistently identified an increased risk or pattern of major birth defects. For children exposed to meprobamate in-utero, one study found no adverse effect on mental or motor development or IQ scores.
Embryofetal development studies in animals have not been completed.
In a published pre-and post-natal development animal study, pregnant mice administered carisoprodol orally at 300, 750, or 1200 mg/kg/day (approximately 1-, 2.6-, and 4.1-times the MRHD based on BSA comparison) from 7-days prior to gestation through birth and from lactation through weaning resulted in reduced fetal weights, postnatal weight gain, and postnatal survival at 2.6-and 4.1-times the MRHD.
Data from published literature report that carisoprodol and its metabolite, meprobamate, are present in breastmilk. There are no data on the effect of carisoprodol on milk production. There is one report of sedation in an infant who was breastfed by a mother taking carisoprodol (see Clinical Considerations). Because there have been no consistent reports of adverse events in breastfed infants over decades of use, the developmental and health benefits of breastfeeding should be considered along with the mother's clinical need for carisoprodol tablets USP and any potential adverse effects on the breastfed infant from carisoprodol tablets USP or from the underlying maternal condition.
Infants exposed to carisoprodol through breast milk should be monitored for sedation.
The safety and pharmacokinetics of carisoprodol tablets USP in patients with renal impairment have not been evaluated. Since carisoprodol tablets USP are excreted by the kidney, caution should be exercised if carisoprodol tablets USP are administered to patients with impaired renal function. Carisoprodol USP is dialyzable by hemodialysis and peritoneal dialysis.
The safety and pharmacokinetics of carisoprodol tablets USP in patients with hepatic impairment have not been evaluated. Since carisoprodol tablets USP is metabolized in the liver, caution should be exercised if carisoprodol tablets USP is administered to patients with impaired hepatic function.
Carisoprodol tablets USP contains carisoprodol USP, a Schedule IV controlled substance. Carisoprodol USP has been subject to abuse, misuse, and criminal diversion for nontherapeutic use [see Warnings and Precautions (5.2)].
Abuse of carisoprodol USP poses a risk of overdosage which may lead to death, CNS and respiratory depression, hypotension, seizures and other disorders [see Warnings and Precautions (5.2) and Overdosage (10)]. Patients at high risk of carisoprodol tablets USP abuse may include those with prolonged use of Carisoprodol USP, with a history of drug abuse, or those who use carisoprodol tablets USP in combination with other abused drugs.
Prescription drug abuse is the intentional non-therapeutic use of a drug, even once, for its rewarding psychological effects. Drug addiction, which develops after repeated drug abuse, is characterized by a strong desire to take a drug despite harmful consequences, difficulty in controlling its use, giving a higher priority to drug use than to obligations, increased tolerance, and sometimes physical withdrawal. Drug abuse and drug addiction are separate and distinct from physical dependence and tolerance (for example, abuse or addiction may not be accompanied by tolerance or physical dependence) [see Drug Abuse and Dependence (9.3)].
Tolerance is when a patient's reaction to a specific dosage and concentration is progressively reduced in the absence of disease progression, requiring an increase in the dosage to maintain the same. Physical dependence is characterized by withdrawal symptoms after abrupt discontinuation or a significant dose reduction of a drug. Both tolerance and physical dependence have been reported with the prolonged use of carisoprodol tablets USP. Reported withdrawal symptoms with carisoprodol tablets USP include insomnia, vomiting, abdominal cramps, headache, tremors, muscle twitching, anxiety, ataxia, hallucinations, and psychosis. Instruct patients taking large doses of carisoprodol tablets USP or those taking the drug for a prolonged time to not abruptly stop carisoprodol tablets USP [see Warnings and Precautions (5.2)].
Overdosage of carisoprodol tablets USP commonly produces CNS depression. Death, coma, respiratory depression, hypotension, seizures, delirium, hallucinations, dystonic reactions, nystagmus, blurred vision, mydriasis, euphoria, muscular incoordination, rigidity, and/or headache have been reported with carisoprodol tablets USP overdosage. Serotonin syndrome has been reported with carisoprodol USP intoxication. Many of the carisoprodol USP overdoses have occurred in the setting of multiple drug overdoses (including drugs of abuse, illegal drugs, and alcohol). The effects of an overdose of carisoprodol tablets USP and other CNS depressants (e.g., alcohol, benzodiazepines, opioids, tricyclic antidepressants) can be additive even when one of the drugs has been taken in the recommended dosage. Fatal accidental and non-accidental overdoses of carisoprodol tablets USP have been reported alone or in combination with CNS depressants.
Treatment of Overdosage
Basic life support measures should be instituted as dictated by the clinical presentation of the carisoprodol tablets USP overdose. Vomiting should not be induced because of the risk of CNS and respiratory depression, and subsequent aspiration. Circulatory support should be administered with volume infusion and vasopressor agents if needed. Seizures should be treated with intravenous benzodiazepines and the reoccurrence of seizures may be treated with phenobarbital. In cases of severe CNS depression, airway protective reflexes may be compromised and tracheal intubation should be considered for airway protection and respiratory support.
For decontamination in cases of severe toxicity, activated charcoal should be considered in a hospital setting in patients with large overdoses who present early and are not demonstrating CNS depression and can protect their airway.
For more information on the management of an overdose of carisoprodol tablets USP, contact a Poison Control Center.
Carisoprodol tablets USP are available as 250 mg and 350 mg circular shaped, white to off white, biconvex tablets. Carisoprodol USP is a white, crystalline powder, having a mild, characteristic odor and a bitter taste. It is slightly soluble in water; freely soluble in alcohol, in chloroform, and in acetone; and its solubility is practically independent of pH. Carisoprodol USP is present as a racemic mixture. Chemically, carisoprodol USP is (±)-2-Methyl-2-propyl-1,3-propanediol carbamate isopropylcarbamate and the molecular formula is C12H24N2O4, with a molecular weight of 260.33. The structural formula is:
In animal studies, muscle relaxation induced by carisoprodol USP is associated with altered interneuronal activity in the spinal cord and in the descending reticular formation of the brain.
A metabolite of carisoprodol, meprobamate, has anxiolytic and sedative properties. The degree to which these properties of meprobamate contribute to the safety and efficacy of carisoprodol tablets USP is unknown.
The pharmacokinetics of carisoprodol USP and its metabolite meprobamate were studied in a crossover study of 24 healthy subjects (12 male and 12 female) who received single doses of 250 mg and 350 mg carisoprodol tablets USP (see Table 2). The exposure of carisoprodol USP and meprobamate was dose proportional between the 250 mg and 350 mg doses. The Cmax of meprobamate was 2.5 ± 0.5 mcg/ml (mean ± SD) after administration of a single 350 mg dose of carisoprodol tablets USP, which is approximately 30% of the Cmax of meprobamate (approximately 8 mcg /ml) after administration of a single 400 mg dose of meprobamate.
| Table 2. Pharmacokinetic Parameters of Carisoprodol USP and Meprobamate
(Mean ± SD, n=24)
| 250 mg Carisoprodol Tablets USP
|| 350 mg Carisoprodol Tablets USP
| Cmax (mcg/mL)
|| 1.2 ± 0.5|| 1.8 ± 1.0
| AUCinf (mcg*hr/mL)
|| 4.5 ± 3.1|| 7.0 ± 5.0
| Tmax (hr)
|| 1.5 ± 0.8|| 1.7 ± 0.8
| T1/2 (hr)
|| 1.7 ± 0.5|| 2.0 ± 0.5
| Cmax (mcg/mL)
|| 1.8 ± 0.3|| 2.5 ± 0.5
| AUCinf (mcg*hr/mL)
|| 32 ± 6.2|| 46 ± 9.0
| Tmax (hr)
|| 3.6 ± 1.7|| 4.5 ± 1.9
| T1/2 (hr)
|| 9.7 ± 1.7|| 9.6 ± 1.5
Food Effect: Co-administration of a high-fat meal with carisoprodol USP (350 mg tablet) had no effect on the pharmacokinetics of carisoprodol. Therefore, carisoprodol tablets USP may be administered with or without food.
Metabolism: The major pathway of carisoprodol USP metabolism is via the liver by cytochrome enzyme CYP2C19 to form meprobamate. This enzyme exhibits genetic polymorphism (see Patients with Reduced CYP2C19 Activity below).
Excretion: Carisoprodol USP is eliminated by both renal and non-renal routes with a terminal elimination half-life of approximately 2 hours. The half-life of meprobamate is approximately 10 hours.
Sex: Exposure of carisoprodol USP is higher in female than in male subjects (approximately 30 - 50% on a weight adjusted basis). Overall exposure of meprobamate is comparable between female and male subjects.
Patients with Reduced CYP2C19 Activity: Carisoprodol tablets USP should be used with caution in patients with reduced CYP2C19 activity. Published studies indicate that patients who are poor CYP2C19 metabolizers have a 4-fold increase in exposure to carisoprodol, and concomitant 50% reduced exposure to meprobamate compared to normal CYP2C19 metabolizers. The prevalence of poor metabolizers in Caucasians and African Americans is approximately 3 - 5% and in Asians is approximately 15 - 20%.
Long term studies in animals have not been performed to evaluate the carcinogenic potential of carisoprodol.
Carisoprodol tablets USP was not formally evaluated for genotoxicity. In published studies, carisoprodol USP was mutagenic in the in vitro mouse lymphoma cell assay in the absence of metabolizing enzymes, but was not mutagenic in the presence of metabolizing enzymes. Carisoprodol USP was clastogenic in the in vitro chromosomal aberration assay using Chinese hamster ovary cells with or without the presence of metabolizing enzymes. Other types of genotoxic tests resulted in negative findings. Carisoprodol USP was not mutagenic in the Ames reverse mutation assay using S. typhimurium strains with or without metabolizing enzymes, and was not clastogenic in an in vivo mouse micronucleus assay of circulating blood cells.
Impairment of Fertility
Carisoprodol tablets USP was not formally evaluated for effects on fertility. A published reproductive study in which female mice received carisoprodol orally at doses of 300, 750, or 1200 mg/kg/day (approximately 1, 2.6, and 4.1 times the MRHD of 1400 mg per day [350 mg QID] based on body surface area [BSA] comparison) from 1-week prior to mating, to 27-weeks post-mating found no alteration in fertility although an alteration in reproductive cycles characterized by a greater time spent in estrus was observed at a carisoprodol dose of 1200 mg/kg/day. In a 13week toxicology study that did not determine fertility, mouse testes weight and sperm motility were reduced at a dose of 1200 mg/kg/day (maternal doses equivalent to 4.2-times the MRHD based on BSA comparison). In both studies, the no effect level was 750 mg/kg/day, corresponding to approximately 2.6-times the MRHD based on a BSA comparison. The significance of these findings for human fertility is not known.
The safety and efficacy of carisoprodol tablets USP for the relief of acute, idiopathic mechanical low back pain was evaluated in two, 7-day, double blind, randomized, multicenter, placebo controlled, U.S. trials (Studies 1 and 2). Patients had to be 18 to 65 years old and had to have acute back pain (≤ 3 days of duration) to be included in the trials. Patients with chronic back pain; at increased risk for vertebral fracture (e.g., history of osteoporosis); with a history of spinal pathology (e.g., herniated nucleus pulposus, spondylolisthesis or spinal stenosis); with inflammatory back pain, or with evidence of a neurologic deficit were excluded from participation. Concomitant use of analgesics (e.g., acetaminophen, NSAIDs, tramadol, opioid agonists), other muscle relaxants, botulinum toxin, sedatives (e.g., barbiturates, benzodiazepines, promethazine hydrochloride), and anti-epileptic drugs was prohibited.
In Study 1, patients were randomized to one of three treatment groups (i.e., carisoprodol tablets USP 250 mg, carisoprodol tablets USP 350 mg, or placebo) and in Study 2 patients were randomized to two treatment groups (i.e., carisoprodol tablets USP 250 mg or placebo). In both studies, patients received study medication three times a day and at bedtime for seven days.
The primary endpoints were the relief from starting backache and the global impression of change, as reported by patients, on Study Day 3. Both endpoints were scored on a 5-point rating scale from 0 (worst outcome) to 4 (best outcome) in both studies. The primary statistical comparison was between the carisoprodol tablets USP 250 mg and placebo groups in both studies.
The proportion of patients who used concomitant acetaminophen, NSAIDs, tramadol, opioid agonists, other muscle relaxants, and benzodiazepines was similar in the treatment groups.
The results for the primary efficacy evaluations in the acute, low back pain studies are presented in Table 3.
| Table 3. Results of the Primary Efficacy Endpointsa in Studies 1 and 2
|| Carisoprodol Tablets USP
| Carisoprodol Tablets USP
| 1|| Number of Patients
|| n=269|| n=264|| n=273
| Relief from Starting Backache, Mean (SE) b
|| 1.4 (0.1)|| 1.8 (0.1)|| 1.8 (0.1)
| Difference between carisoprodol tablets USP and Placebo, Mean (SE) b (95% CI)|| 0.4|
| Global Impression of Change, Mean (SE) b
|| 1.9 (0.1)|| 2.2 (0.1)|| 2.2 (0.1)
| Difference between carisoprodol tablets USP and Placebo, Mean (SE) b (95% CI)|| 0.2|
| 2|| Number of Patients
|| n=278|| n=269|
| Relief from Starting Backache, Mean (SE) b
|| 1.1 (0.1)|| 1.8 (0.1)|
| Difference between carisoprodol tablets USP and Placebo, Mean (SE) b (95% CI)|| 0.7|
| Global Impression of Change, Mean (SE) b
|| 1.7 (0.1)|| 2.2 (0.1)|
| Difference between carisoprodol tablets USP and Placebo, Mean (SE) b (95% CI)|| 0.5|
|a The primary efficacy endpoints (Relief from Starting Backache and Global Impression of Change) were assessed by the patients on Study Day 3. These endpoints were scored on a 5-point rating scale from 0 (worst outcome) to 4 (best outcome).
b Mean is the least squared mean and SE is the standard error of the mean. The ANOVA model was used for the primary statistical comparison between the carisoprodol tablets USP 250 mg and placebo groups.
NDC 42543-434-01: Bottles of 100 tablets
NDC 42543-434-05: Bottles of 500 tablets
NDC 42543-434-10: Bottles of 1000 tablets
Carisoprodol Tablets USP, 350 mg: circular shaped, biconvex, white to off white colored, uncoated tablets debossed "S" and "435" on one side and plain on the other side, available as follows:
NDC 42543-435-01: Bottles of 100 tablets
NDC 42543-435-05: Bottles of 500 tablets
NDC 42543-435-10: Bottles of 1000 tablets
Store at 20° to 25°C (68° to 77°F). [See USP Controlled Room Temperature].
Advise patients that carisoprodol tablets USP may cause drowsiness and/or dizziness, and has been associated with motor vehicle accidents. Patients should be advised to avoid taking carisoprodol tablets USP before engaging in potentially hazardous activities such as driving a motor vehicle or operating machinery [see Warnings and Precautions (5.1)].
Avoidance of Alcohol and Other CNS Depressants
Advise patients to avoid alcoholic beverages while taking carisoprodol tablets USP and to check with their doctor before taking other CNS depressants such as benzodiazepines, opioids, tricyclic antidepressants, sedating antihistamines, or other sedatives [see Warnings and Precautions (5.1)].
Carisoprodol tablets USP Should Only Be Used for Short-Term Treatment
Advise patients that treatment with carisoprodol tablets USP should be limited to acute use (up to two or three weeks) for the relief of acute, musculoskeletal discomfort. In the post-marketing experience with carisoprodol tablets USP, cases of dependence, withdrawal, and abuse have been reported with prolonged use. If the musculoskeletal symptoms still persist, patients should contact their healthcare provider for further evaluation.
Advise nursing mothers using carisoprodol tablets USP to monitor neonates for signs of sedation [see Use in Specific Populations (8.2)].
Strides Pharma Science Ltd.
Puducherry - 605014, India
Strides Pharma Inc.
East Brunswick, NJ 08816
|Labeler - Vensun Pharmaceuticals, Inc. (078310501)|
|Strides Pharma Science Limited||871402375||MANUFACTURE(42543-434)|